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Abstract
Studies in malaria patients indicate that higher frequencies of peripheral blood CD4
+ Foxp3
+ CD25
+ regulatory T (Treg) cells
correlate with increased blood parasitemia. This observation implies that Treg cells impair pathogen clearance and thus may
be detrimental to the host during infection. In C57BL/6 mice infected with Plasmodium berghei ANKA, depletion of Foxp3
+
cells did not improve parasite control or disease outcome. In contrast, elevating frequencies of natural Treg cells in vivo
using IL-2/anti-IL-2 complexes resulted in complete protection against severe disease. This protection was entirely
dependent upon Foxp3
+ cells and resulted in lower parasite biomass, impaired antigen-specific CD4
+ T and CD8
+ T cell
responses that would normally promote parasite tissue sequestration in this model, and reduced recruitment of
conventional T cells to the brain. Furthermore, Foxp3
+ cell-mediated protection was dependent upon CTLA-4 but not IL-10.
These data show that T cell-mediated parasite tissue sequestration can be reduced by regulatory T cells in a mouse model of
malaria, thereby limiting malaria-induced immune pathology.
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Introduction
Severe malaria syndromes, including cerebral malaria (CM),
claim the lives of approximately 900,000 people annually, mostly
children under the age of 5 living in sub-Saharan Africa [1]. The
mechanisms of CM pathogenesis remain poorly understood, since
studies in humans are often restricted to post-mortem examina-
tions. In particular, the roles played by the host immune response
in either driving or preventing CM are unclear. It is possible that
the immune response could be over-exuberant in some CM
patients or lethargic in others, the balance of which may depend
on the patient’s and the parasite’s genetic background. Several
studies in malaria patients have reported associations between
higher frequencies of peripheral blood regulatory T (Treg) cells
and increased parasitemia [2,3,4]. However, these studies
provided limited mechanistic insight into the role of Treg cells
in severe malarial disease.
Under homeostatic conditions, Treg cells limit potentially
aberrant T cell responses, thus preventing autoimmunity [5].
However, they can also impair effective pathogen clearance
[6,7,8], while potentially playing a beneficial role in preventing
immune-pathology during infection. The molecular mechanisms
by which Treg cells perform these functions are incompletely
understood, but have been reported to involve production of
cytokines such as TGFb and IL-10, and increased expression of
the negative regulatory molecule CTLA-4 [9,10,11]. Furthermore,
it is not known whether Treg cells act directly upon conventional
T cells or on accessory cells such as antigen-presenting cells.
Nevertheless, Treg cells are often viewed as detrimental during
infection, since they may impede the generation of effective
pathogen-specific T cell responses. Thus, an emerging paradigm is
that Treg cells block T cell-mediated clearance of malaria parasites
in humans, facilitating an increase in parasitemia.
The direct study of immune mechanisms in malaria patients is
problematic for obvious practical and ethical reasons. Therefore,
mouse models of severe and non-severe malaria have been
employed to study the immune response to infection. Studies in
an experimental model of cerebral malaria (ECM) caused by
infection of C57BL/6 mice with P. berghei ANKA (PbA) have
highlighted the important role played by various immune cells in
disease pathogenesis, including CD4
+ T cells, CD8
+ T cells,
conventional dendritic cells and Natural Killer (NK) cells
[12,13,14,15,16,17,18]. In mice that succumb to ECM, parasite
biomass is poorly controlled and there is clear evidence of immune-
mediated parasite tissue sequestration [19]. Until recently, the
deleterious role proposed for Treg cells in studies of human malaria
has been difficult to test in mice, due to the lack of appropriate
reagents [20,21]. Our initial studies indicated a detrimental role for
Treg cells because depletion of CD25
hi cells prior to infection, the
majority of which were Treg cells, protected mice from ECM and
was associated with increased antigen-specific CD4
+ T cell
responses [20]. Recently however, specific depletion of FoxP3
+
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role for these cells in mediating disease [22]. Although the effect of
Treg cell depletion on T cell responses and pathogen burden was
not studied [22], given that ECM is mediated by pathogenic T cells
that promote parasite tissue sequestration [19], we hypothesized
that under certain conditions, Treg cells can suppress deleterious T
cell responses and protect against ECM.
One approach to manipulate Treg cell numbers in vivo has
been to use IL-2/anti-IL-2 antibody complexes to potentiate IL-2
signalling and drive expansion of FoxP3
+ Treg cells [23]. Certain
monoclonal antibodies (mAbs) bind to IL-2 in such a way that its
signalling capacity is preserved, while its in vivo half-life is
dramatically extended [24]. Moreover, different mAbs against IL-
2 bind to different regions of the molecule, thus skewing its
signalling capacity [25]. For example in mice, IL-2 bound to S4B6
mAb is not capable of interacting with the high affinity,
heterotrimeric IL-2 receptor, but does interact with the lower
affinity heterodimeric receptor. In contrast, IL-2 bound to JES6-
1A12 mAb retains the ability to interact with the higher affinity
receptor. IL-2/anti-IL-2 complexes profoundly alter lymphocyte
dynamics during homeostasis, autoimmunity and vaccination
[23,25,26,27,28]. Recently, IL-2/JES6-1A12 was shown to
expand Treg populations, prevent auto-immunity and induce
long term graft tolerance [23]. Here, we show for the first time that
while removal of naturally-occurring Treg cells minimally affects
the course of disease, increasing their numbers in vivo throughout
the course of infection via IL-2/anti-IL-2 antibody complexes
allows these cells to protect against ECM.
Results
Total Foxp3
+ cell depletion has minimal effects on
pathogen burden, T cell responses or clinical outcome in
ECM
The foxp3-DTR transgenic (DEREG) mouse was recently used
to deplete Foxp3
+ cells prior to and over the course of PbA
infection, with no impact on susceptibility to ECM [22]. We
employed the same system here to study the effect of Foxp3
+ cell
depletion on T cell responses and pathogen burden during ECM.
Consistent with the published data, in our hands DEREG mice
depleted of Foxp3
+ cells the day prior to, and over the course of
infection (Figure 1A), remained as susceptible to ECM as Foxp3
+
cell replete DEREG mice (data not shown). Furthermore, we
observed no change in whole body parasite burden (Figure 1B);
with a trend towards an increase in the splenic IFNc
+ CD4
+ T cell
response (Figure 1C). These data show that the depletion of
Foxp3
+ cells had little effect on pathogen burden or disease
outcome during ECM.
IL-2/anti-IL-2 complexes protect against ECM
Since removal of Foxp3
+ cells had no effect on disease
progression, we next examined whether increasing numbers of
Foxp3
+ cells would impact upon ECM development. Therefore
C57BL/6 mice were infected with PbA and immediately treated
with a single dose of IL-2/JES6-1A12 (hereafter referred to as IL-
2Jc) or IL-2/S4B6 (IL-2Sc) complexes. The IL-2Jc complex binds
the high affinity heterotrimeric IL-2 receptor to drive Treg cell
expansion, while the IL-2Sc complex binds the lower affinity
heterodimeric IL-2 receptor resulting in the expansion of activated
CD8
+ T cells and NK cells [25]. Control mice that received rat
IgG displayed clinical signs of illness from day 6 post-infection (p.i),
and succumbed to infection with neurological symptoms typical of
ECM with a Median Survival Time (MST) of 8 days (Figure 2A).
Mice treated with IL-2Sc were also susceptible to ECM (MST: 7
days), demonstrating that IL-2Sc afforded no protection against
infection (Figure 2A). In stark contrast, IL-2Jc treated, infected
mice, rarely displayed ECM symptoms and were protected from
ECM-related morbidity, dying instead from hyperparasitemia with
an MST of 28 days (Figure 2A). Mice treated with S4B6 alone,
JES6-1A12 alone or recombinant IL-2 alone, were as susceptible
to ECM as control mice (Figures 2B & 2C). Together, these data
demonstrate a specific capacity for IL-2Jc, but not its component
parts in isolation or an alternative IL-2 antibody complex (IL-2Sc),
to protect against ECM.
To investigate the timing and dosing requirements for IL-2Jc-
mediated protection, PbA-infected mice were treated on days 0 or
2 p.i., or on both days with either a standard IL-2Jc dose (1.5ug
cytokine: 50ug antibody) (Figure 2D left) or a ten-fold lower dose
(Figure 2D right). Control mice displayed clinical signs of disease
from day 6 p.i., with 100% of mice succumbing to ECM by day 8
p.i. Only mice that had received a standard IL-2Jc dose on day 0
were protected from ECM. Importantly, mice receiving a delayed
IL-2Jc dose on day 2 p.i. were completely susceptible to ECM.
Thus, IL-2Jc protects against ECM only when administered at the
time of infection.
IL-2Jc prevents the rapid increase in parasite burden
associated with ECM
C57BL/6 mice typically display ECM symptoms when blood
parasitemia reaches ,7–10% parasitized red blood cells (pRBCs)
(Figure 3A). Blood parasitemia in IL-2Jc-treated mice was similar
to control, infected mice on days 4 & 5 p.i. (Figure 3A). However,
from day 6 p.i. onwards, when clinical symptoms appeared in
control mice, IL-2Jc treated mice displayed significantly lower
blood parasitemia for the following 3 days, only rising again from
day 10 p.i. onwards (Figure 3A). While blood parasitemia has been
routinely used to monitor disease progression, it is now recognised
that measurements of total parasite biomass in the whole body
offer a better correlate of the disease status of malaria patients
[29]. To assess parasite biomass in infected mice, we used a
transgenic PbA strain engineered to constitutively express firefly
luciferase (PbA-luc) [20]. The bioluminescence generated by PbA-
luc parasites at any given time is directly proportional to the sum
of parasites in the tissues and circulating blood of the infected
animal [19,20,30] (Figure 3B). IL-2Jc-treated, PbA-luc-infected
Author Summary
Severe malaria can kill people via complications such as
cerebral malaria. The number of malaria parasites in the
body is a major determinant of whether a patient will
develop severe disease. T cells are thought to help control
parasite numbers, but regulatory T cells, which are known
to dampen immune responses, are present at a greater
frequency in the blood of malaria patients with the highest
parasitemia, suggesting that these cells might impair
parasite control. Our experiments in a mouse model of
cerebral malaria show for the first time that regulatory T
cells can contribute to protection against disease. Specif-
ically, our data shows that accumulation of parasites in
host tissues can be promoted by anti-parasitic T cell
responses, and that regulatory T cells can reduce this
parasite tissue sequestration and protect against experi-
mental cerebral malaria if their numbers are sufficiently
elevated. These results suggest that regulatory T cells can
help reduce pathogenic T cell responses during experi-
mental infection and protect against malaria induced
immune pathology.
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control mice on day 6 p.i., when control animals displayed severe
ECM symptoms. Moreover, following whole body perfusion to
remove circulating RBCs, brains from IL-2Jc-treated mice also
exhibited significantly lower parasite sequestration than brains
from control animals (p,0.05) (Figure 3C). These data demon-
strate that IL-2Jc-mediated protection against ECM was associ-
ated with lower parasite biomass and reduced pRBC brain
sequestration.
Effect of IL-2Jc on recruitment of leukocytes to the brain
ECM is associated with the recruitment of CXCR3
+ leukocytes
to the brain [13,31,32,33,34], including T cells responsible for
disease pathology [16,18]. On day 6 p.i., the recruitment of CD8
+
and CD4
+ T cells, but not NK cells, to the brain was significantly
reduced by IL-2Jc treatment, compared with mice receiving either
IL-2Sc or control treatment (Figure 4). Furthermore, Treg cell
numbers were significantly higher in IL-2Jc-treated mice com-
pared to all other groups studied (Figure 4). These data indicated
that IL-2Jc-mediated protection was associated both with a specific
blockade of conventional T cell recruitment to the brain, and also
an increase in the number of Treg cells in this tissue site.
IL-2Jc–mediated protection is associated with
suppression of effector CD8
+ and CD4
+ T cells, and
expansion of Treg cells
CD8
+ T cells play a key role in ECM pathology [16,18]. A
previous study using a transgenic PbA strain expressing model T
cell epitopes showed that antigen-specific CD8
+ T cells are primed
in the spleen [35]. We employed this experimental system to assess
the fate of antigen-specific CD8
+ T cells in IL-2Jc-treated mice
during ECM. OVA-specific, congenic (CD45.1) CD8
+ T (OTI)
cells were transferred into mice prior to infection with OVA-
transgenic PbA( PbTG) or a non-OVA-expressing control parasite
(PbG). On day 6 p.i., splenic OTI cell numbers and activation
status, via Granzyme B (GzmB) expression, were assessed
(Figure 5A). OTI cells were not detected in the spleens of naı ¨ve
mice or mice infected with PbG (Figure 5A). The expression of
GzmB was detected in ,30% of endogenous (CD45.1 negative)
CD8
+ T cells in PbG-infected mice, indicating dramatic activation
of CD8
+ T cells at the onset of ECM. In control treated mice
infected with PbTG, OTI cells were readily detected, indicating
antigen-specific activation and proliferation of these cells had
occurred. Moreover, nearly all of these cells expressed GzmB, at a
level similar to activated endogenous CD8
+ T cells. IL-2Jc
treatment at the time of infection dramatically impaired, though
did not abrogate, the OTI CD8
+ T cell response (Figure 5A). This
effect was not apparent in mice treated on day 2 p.i. with IL-2Jc.
Furthermore, mice treated with IL-2Sc displayed a trend towards
an enhanced OTI T cell response compared to control mice,
which is consistent with reports of the stimulatory effect of IL-2Sc
on CD8
+ T cells [25,26,27,28,36]. Together these data demon-
strate that IL-2Jc, when administered on the day of infection,
potently inhibits pathogenic, antigen-specific CD8
+ T cell
responses during ECM.
TobesurethatIL-2Jcdid notstimulateNKcellsorNKTcells,we
examined their expression of the activation markers CD69, GzmB
and IFNc, 24 hours after infection and treatment with IL-2Jc. As
expected,nofurtheractivation ofNKorNKT cells inIL-2Jc-treated
mice was detected relative to control-treated, infected mice; while in
contrast, IL-2Sc-treatment clearly stimulated both NK and NKT
cells (Figure S1A). Furthermore, neither depletion of NK cells with
anti-NK1.1 antibody, nor the absence of invariant chain NKT cells
in B6.Ja18
2/2 mice, impeded either CD4
+ Foxp3
+ T cell expansion
(Figure S1B) or control of parasite burden (Figure S1C) by IL-2Jc.
Together these data indicate that IL-2Jc does not protect against
ECM via activation of NK cells or NKT cells.
PbA infection induces a potent pro-inflammatory cytokine
response in C57BL/6 mice that is strongly associated with ECM
pathogenesis. IFNc is absolutely critical for disease onset
[37,38,39], possibly by promoting PbA tissue sequestration [19].
We found that IL-2Jc administered on the day of infection resulted
in lower serum IFNc levels by day 4 p.i., whereas neither IL-2Sc
nor delayed IL-2Jc treatment had any significant effect (Figure S2).
Examination of the antigen-specific splenic CD4
+ T cell response
indicated an impaired ex vivo proliferative and IFNc recall
response from IL-2Jc treated mice (Figure S3), suggesting that in
vivo CD4
+ T cell responses were impaired by IL-2Jc treatment.
Therefore, we enumerated splenic IFNc-producing CD4
+ T cells
and Treg cells over the course of PbA-infection in mice treated
with IL-2Jc or IL-2Sc. IFNc-producing CD4
+ T cells were
detectable from day 4 p.i. onwards in infected, but not naı ¨ve mice
(Figure 5B). Control saline-treated and IL-2Sc-treated infected
mice had very similar numbers of IFNc
+ CD4
+ T cells on day 4
Figure 1. Total Foxp3
+ cell depletion does not affect parasite burden or disease outcome in ECM. DEREG mice (n=5) were treated with
DT (1mg i.p.) or saline on the day prior to infection, and on days 2 and 4 after infection with PbA. On day 4 p.i., A) Foxp3
+ cell depletion and C) the
magnitude of the IFNc CD4
+ T cell response was determined in the spleen by flow cytometry. B) Whole body parasite burdens were assessed on day
6 p.i.. These data are representative of 2 independent experiments. Mann-Whitney: *p,0.05.
doi:10.1371/journal.ppat.1001221.g001
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+
CD4
+ T cells (p,0.001). Interestingly, the number of IFNc
+ CD4
+
T cells was greatly enhanced if IL-2Jc was administered on day 2
p.i. (p,0.001)(Figure 5B), possibly indicating increased expression
of high affinity IL-2 receptor on these cells by day 2 p.i.. Treg cells
expanded in control, infected mice and numbers peaked on day 4
p.i., before declining by day 6 p.i. (Figure 5C), consistent with
previous reports [20,21,40]. Infected mice treated with IL-2Sc
exhibited almost identical Treg cell expansion kinetics to that of
control treated mice (Figure 5C), consistent with the notion that
IL-2Sc has little impact on Treg cell numbers [25]. Strikingly, IL-
2Jc treatment at the time of PbA infection resulted in a dramatic
expansion in Treg cell numbers with a .6-fold increase by day 2
p.i., peaking at day 4 p.i. (,3.5-fold greater numbers than in
control treated mice), before retracting somewhat by day 6 p.i.,
although numbers still remained ,4-fold greater than in IL-2Sc
and control treated groups. In contrast, delaying IL-2Jc treatment
until day 2 p.i., resulted in very little enhanced Treg cell
expansion. Thus, the protection afforded by IL-2Jc treatment at
the time of PbA infection was associated with a dramatic and
sustained elevation of Treg cell numbers over the course of
infection. Taken together, these data show that IL-2Jc-mediated
protection against ECM was associated with an expansion of
CD4
+ Treg cells and an accompanying impairment of the
conventional CD8
+ and CD4
+ T cell responses.
IL-2Jc treatment during ECM causes natural Treg cells to
proliferate and express higher levels of Foxp3, IL-10 and
CTLA-4
We next determined whether the increase in Treg cell numbers
caused by IL-2Jc treatment during infection was the result of
natural Treg cell expansion, or de novo conversion of naı ¨ve,
Foxp3
2 CD4
+ T cells into Treg cells. Foxp3
+ CD4
+ natural Treg
cells and Foxp3
2 CD4
+ T cells were sorted from the spleens of
naı ¨ve foxp3
gfp/gfp mice [41], and transferred into C57BL/6 mice.
On the same day, these mice were infected, and treated either with
IL-2Jc or saline. At the peak of Treg cell expansion (4 days later),
splenic GFP
+ Foxp3
+ CD4
+ Treg cells were enumerated. These
cells were readily detected in mice that received GFP
+ natural
Treg cells, and indeed their numbers were boosted by IL-2Jc
treatment (Figure 6A). However, in mice receiving GFP
2 non-
Treg CD4
+ T cells, we observed no evidence of their conversion
into Foxp3
+ Treg cells either spontaneously during infection or
after stimulation with IL-2Jc. These data indicate that IL-2Jc
treatment during ECM triggers natural Treg cell expansion, but
not conversion of Foxp3
2 CD4
+ T cells to a Foxp3
+ phenotype.
Figure 2. IL-2/anti-IL-2 complex protects against ECM. A) C57BL/6 mice (n=10–15) were infected with PbA, and treated on day 0 p.i. with
complexes IL-2Jc, IL-2Sc, or with control rat IgG. Mice were monitored for survival. Log Rank: ***p,0.001. This experiment is representative of .5
independent experiments. B) C57BL/6 mice (n=5), infected as above, were treated i.p. with 0.5mg of S4B6, JES6-1A12 or control mAb on days 0 & 3
p.i., and monitored for survival. These data are representative of 2 independent experiments. C) C57BL/6 mice (n=5), infected as above, were treated
i.p. with 1.5mg of recombinant mouse IL-2 on the day of infection and monitored for survival. These data are representative of 2 independent
experiments. D) Graphs illustrate data from a single representative experiment of 2 in which infected mice were treated i.p. on days indicated with
either a standard dose of IL-2Jc (left graph) or a 10-fold lower dose (right graph). Mice were scored for clinical symptoms from day 5 (120 hours p.i.).
doi:10.1371/journal.ppat.1001221.g002
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by IL-2Jc was dependent upon infection. Naı ¨ve and infected groups
of mice were treated with IL-2Jc or control saline. Four days later,
the number of splenic Foxp3
+ CD4
+ T cells was determined
(Figure 6B). Consistent with previous reports [23,25], substantial
Treg cell expansion was observed in both naı ¨ve and infected mice,
demonstrating that this phenomenon is not dependent on infection.
Importantly, however, when we assessed direct ex vivo production
of cytokines by Treg cells (by intracellular cytokine staining with no
in vitro stimulation) (Figure 6B), we noted that while expanded
Treg cells in naı ¨ve mice made little IL-10, those in IL-2Jc treated,
infected mice, made significantly higher amounts of this cytokine
than those from control, infected mice. A small number of Treg
cells from IL-2Jc-treated, infected mice, also appeared to make
IFNc, but this response was much lower than the IL-10 response
(Figure 6B). These data indicate that IL-2Jc triggers the expansion
of IL-10-producing Treg cells during PbA infection. We further
analysed the effects of IL-2Jc on Treg cells, and observed that their
expression of CD25, Foxp3 and CTLA-4 was substantially elevated
by IL-2Jc treatment compared to control saline treated, infected
mice (Figure 6C). Taken together, these data demonstrate that IL-
2Jc treatment triggers the expansion of natural CD4
+ Treg cells,
which then express higher levels of Foxp3, IL-10 and CTLA-4 in
response to PbA infection.
IL-2Jc–mediated protection against ECM is dependent on
Foxp3
+ Treg cells, and CTLA-4, but not IL-10
To determine if Treg cells were important for IL-2Jc mediated
protection against ECM, we employed the DEREG mice [5].
C57BL/6 mice and DEREG mice were infected with PbA, and
treated with IL-2Jc or saline. DT or saline was administered to IL-
2Jc treated DEREG and C57BL/6 mice from day 3 p.i., around
the peak expansion of Treg cells. The following day (day 4 p.i.),
while Treg cell expansion was evident in DEREG mice given IL-
2Jc, depletion of Treg cells (.95% efficacy in this study) was
confirmed in mice that had received DT (Figure 7A). C57BL/6
mice were completely protected from ECM when treated with IL-
2Jc, either with or without DT treatment (Figure 7B), indicating
no side-effects of DT treatment in C57BL/6 mice during PbA-
infection over this time-frame. DEREG mice were equally
susceptible to ECM as C57BL/6 mice, and were protected by
IL-2Jc treatment (Figure 7B). Crucially, IL-2Jc-mediated control
of parasite burdens and protection from disease was completely
abrogated when DEREG mice were treated with DT (Figure 7B &
7C). These data formally demonstrate that Foxp3
+ cells are
responsible for IL-2Jc-mediated protection against ECM.
Since IL-2Jc treatment increased IL-10 and CTLA-4 expression
by Foxp3
+ CD4
+ T cells during infection (Figure 6B & 6C), we
hypothesized that protection was dependent upon these two
molecules. To test this, IL-2Jc-treated, PbA-infected C57BL/6
mice received anti-CTLA-4 or anti-IL-10R blocking antibodies, or
control IgG from day 3 p.i.. Anti-CTLA-4 significantly reduced
IL-2Jc-mediated protection, with .60% of IL-2Jc-treated mice
succumbing to infection with pathogen burdens similar to control
infected mice (Figure 8A & 8B). Anti-IL-10R blockade, on the
other hand, only partially reversed IL-2Jc-mediated protection,
with .60% survival (Figure 8A), and interestingly, further reduced
pathogen burdens in IL-2Jc treated mice (Figure 8B). Both
Figure 3. IL-2Jc treatment reduces parasite biomass during ECM. A) Peripheral blood parasitemia was determined in IL-2Jc-treated and
control treated mice throughout PbA infection. Control mice assessment was stopped when mice began to succumb to infection. B) C57BL/6 mice
were infected with transgenic PbA-luc, expressing luciferase, and i.p. treated with IL-2Jc or control saline on the same day. On day 6 p.i., when control
mice were exhibiting symptoms of ECM, mice were imaged for parasite-derived bioluminescence. Rainbow coloured images depict increasing
intensities of light, from purple to red. Data is summarised on the accompanying graph. C) Perfused brains from mice in B) were also assessed for
parasite biomass; Mann-Whitney: *p,0.05. These data are representative of 3 independent experiments.
doi:10.1371/journal.ppat.1001221.g003
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+ T
cell response that had been impaired by IL-2Jc treatment
(Figure 8C). Since we could detect only a modest role for IL-10
in IL-2Jc mediated protection of wild-type C57BL/6 mice, we
further examined the effect of IL-2Jc treatment in IL-10
2/2 mice,
and found that these animals were significantly protected against
ECM in a CTLA-4-dependent manner (Figure S4). These data
demonstrate that IL-10 is not essential for IL-2Jc-expanded
natural Treg cells to protect against ECM.
In addition, non-IL-2Jc treated mice were also treated with anti-
CTLA-4 or anti-IL-10R blocking antibodies to study their effects
alone on the course of ECM. Anti-CTLA-4 treatment did not alter
disease outcome in saline treated mice (Figure 8A), despite
partially reducing parasite burdens (Figure 8B), while anti-IL-
10R treatment significantly accelerated ECM onset (Figure 8A)
(MST 6.5 days vs. 8 days; p,0.01), with a partial reduction in
parasite burden (Figure 8B). Of note, when anti-IL-10R mAb was
administered from the start of infection, a more substantial
reduction on parasite burden is observed [19].
Taken together, these data demonstrate that when CTLA-4 was
blocked in IL-2Jc treated mice, pathogenic CD4
+ T cell responses
were restored, pathogen burdens were poorly controlled and
protection from ECM was reversed. Thus IL-2Jc mediated
protection against ECM is strongly dependent on Foxp3
+ cells,
and CTLA-4, but not IL-10.
Discussion
T cell responses to infection are generally required for pathogen
control, but can also contribute to disease. The roles of T cells in
the pathogenesis of severe malaria syndromes, including CM, are
unclear. Leukocytes have been observed in the brains of patients
who have died from CM [42,43], but their contribution to CM
pathogenesis is not known. Studies in the ECM model show that T
cells play a critical role in disease pathogenesis [16,18], although
the role of Treg cells in this model remains the subject of debate
[20,21,22]. Data from this study and others [22] suggest that Treg
cells do little to impact on ECM onset, and may in some cases
exacerbate disease [20,21]. Higher Treg cell frequencies have
been associated with elevated blood parasitemia in human malaria
patients [4,44,45], suggesting that Treg cells impair pathogen
clearance during malaria. However, one report demonstrated that
anti-CD25 treatment of ECM-resistant BALB/c mice increased
the incidence of neurological symptoms during secondary PbA
challenge [46], suggesting Treg cells might be protective against
ECM. Here, we report that Treg cells can protect against ECM
following their expansion in vivo. Thus, while Treg cell responses
during ECM are usually insufficient to control pathogenic T cells,
and Treg cell ablation has no effect on pathogen burden or disease
outcome, if present in large enough numbers, Treg cells can
prevent disease. This is the first report to clearly show that CD4
+
Figure 4. IL-2Jc blocks conventional T cell recruitment to the brain during ECM. Brain sequestered leukocytes from naı ¨ve, PbA-infected &
saline treated, and PbA-infected, IL-2Jc or IL-2Sc-treated C57BL/6 mice (n=5) were isolated on day 6 p.i., when control, infected mice were displaying
ECM symptoms, and phenotyped by flow cytometry. Mann-Whitney: *p,0.05; **p,0.01. These data are representative of 3 independent
experiments.
doi:10.1371/journal.ppat.1001221.g004
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+ Treg cells can play a direct protective role during
experimental malaria infection. However, it is important to bear
in mind that Treg-mediated protection was only achieved by
treatment with IL-2Jc from the start of infection, and this
therapeutic opportunity will not exist in human malaria patients.
Thus, alternative approaches to rapidly expand Treg cell numbers
in a clinical setting would have to be considered for therapeutic
effect.
Previous data from our laboratory showed that anti-CD25
(PC61) monoclonal antibody treatment, partially depleted/
blocked Treg cells (i.e.,, affecting only those cells expressing high
levels of CD25), enhanced anti-parasitic CD4
+ T cell responses,
and reduced both parasite burden and ECM incidence [20].
These data were interpreted to mean that natural Treg cells
normally impair pathogen clearance, and thus help to promote
ECM. However, it is now clear from this work, and from another
recent report, that total depletion of natural Treg cells does not
protect against ECM [22]. The discrepancy between the outcome
of partial and total Treg cell depletion in ECM are unresolved at
present, but could be linked to the fact that anti-CD25 mAb-
treated mice retain a population of CD25
lo Foxp3
+ CD4
+ T cells
that can display plasticity in vivo [47], and might therefore
contribute to protection from disease.
Pathogen control is clearly inefficient during ECM, with little
evidence that T cells provide any protection against infection. To
date, only NK cells have been reported to mediate some pathogen
control during ECM [13]. However, NK cell depletion in IL-2Jc-
treated mice did not prevent protection from ECM, indicating that
these cells were not targets for IL-2Jc and did not contribute to
enhanced parasite control. We recently showed that T cells
promote the accumulation of pRBC in multiple tissue sites during
PbA infection, and that depletion of either CD4
+ or CD8
+ T cells
to protect from ECM dramatically reduced parasite tissue
sequestration [19]. Furthermore, lymphocyte-deficient B6.RAG1-
deficient mice failed to develop ECM and had markedly reduced
parasite burdens compared to control animals and B cell-deficient
mice following PbA infection [19]. Therefore, in C57BL/6 mice,
PbA tissue sequestration is promoted by host T cell responses,
possibly by the conditioning host tissue endothelial cells via
cytokines to allow binding of pRBC, as described by others [48].
Our earlier studies on anti-CD25 mAb treatment of PbA-
infected mice indicated that early blockade/depletion of CD25
hi
Treg cells allowed the generation of an enhanced anti-parasitic
CD4
+ T cell response that was accompanied by recovery and
expansion of CD25
hi Treg cells during the course of infection [20].
Furthermore, our current data indicates that the most likely
explanation for the protective effects of in vivo expanded Treg
cells is the suppression of pathogenic T cell expansion that would
otherwise promote parasite tissue sequestration. Thus, we propose
a model whereby naturally occurring CD25
hi Treg cells suppress
the development of potent anti-parasitic immunity early during
PbA infection and their depletion/blockade results in enhanced
Figure 5. IL-2Jc-mediated protection is associated with impaired expansion of antigen-specific CD8
+ T cells, reduced effector CD4
+
T cell responses, and Treg cell expansion. A) C57BL/6 mice were adoptively transferred with 10,000 CD8
+ CD45.1
+ OTI T cells, and infected with
SIINFEKL-expressing transgenic PbTG. Control mice were infected with non-SIINFEKL-expressing PbG parasites. PbTG-infected mice were i.p. treated
with IL-2Jc (day 0 or day 2), IL-2Sc (day 0), or control saline. On day 6 p.i., when control mice were displaying ECM symptoms, splenic CD8
+ T cells
(gated in FACS plots) were assessed for the presence of CD45.1
+ SIINFEKL-specific T cells, and expression of the activation marker, GzmB. The graph
indicates the number of CD45.1
+ CD8
+ SIINFEKL-specific T cells per spleen. Mann-Whitney * p,0.05. These data are representative of 2 independent
experiments. B&C) C57BL/6 mice (n=5) were infected with PbA, and i.p. treated with IL-2Jc (day 0 or day 2 p.i), IL-2Sc (day 0) or control saline. On days
indicated, splenocytes were assessed directly ex vivo for the number of B) IFNc-producing effector CD4
+ T cells and C) CD4
+ Foxp3
+ Treg cells. Mann-
Whitney: ***p,0.001. These data are representative of 2 independent experiments.
doi:10.1371/journal.ppat.1001221.g005
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+ T cells responses, reducing both parasite
burdens and the risk of severe pathology. However, there also
appears to be an important role for the remaining CD25
lo Foxp3
+
CD4
+ T cells in achieving a balance between emerging anti-
parasitic immunity and immune-pathology in anti-CD25mAb-
treated mice, as indicated by the failure of DT-mediated Treg cell
depletion in DEREG mice to protect against ECM. A role for IL-
10-producing inducible regulatory T cells [40] and/or IL-10/
IFNc-producing Th1 cells [4] identified in P. yoelii-infected mice
and malaria patients, respectively, may also contribute to this latter
process. Our data reported in this study shows that if Treg cells
can be expanded sufficiently via IL-2Jc during PbA infection, they
can suppress normally pathogenic T cell responses, and prevent
parasite tissue sequestration and ECM. Hence, Treg cells could
have two potentially important roles during PbA infection
(Figure 9). First, they could suppress the early generation of anti-
parasitic CD4
+ T cells responses that are detrimental to the host,
and second, they can modulate pathogenic T cell responses to
reduce parasite tissue sequestration later during infection. This
latter effect may allow better clearance of parasites in the spleen,
thus lowering parasite burden. Again, we do not rule out the
possibility that inducible regulatory T cells may also play a role in
protecting against disease later in infection, and even restricting
parasite tissue sequestration.
Treg cell-mediated protection against ECM was exquisitely
sensitive to the timing of IL-2Jc treatment. Delaying treatment by
48 hours caused the selective expansion of conventional CD4
+ T
cells rather than Treg cells, presumably due to infection-induced
expression of high affinity IL-2 receptor by the former cell
population. However, this expansion of conventional CD4
+ T cells
was unable to control parasite growth and failed to protect from
ECM. Treg cell depletion from day 3 p.i., completely abrogated
IL-2Jc-mediated protection, showing that IL-2Jc-expanded Treg
cells were responsible for protection from ECM. Clearly, there is a
fine balance between the activation and expansion of anti-parasitic
T cell responses and the emergence of disease-protective Treg cells
that determines the outcome of PbA infection. Whether such an
intimate relationship between these two different types of T cells
exists during human malaria remains to be determined. Never-
theless, our data suggests a more complex temporal and spatial
relationship between emerging anti-parasitic T cell responses
required for control of parasite growth and the functions of Treg
cells that may protect against disease, than has previously been
recognised.
Treg cells function via multiple mechanisms, including CTLA-4
[11], IL-10, TGFb and IL-2-deprivation [10]. We found that Treg
cell-mediated protection against ECM required CTLA-4, but was
only modestly affected by IL-10 blockade. Previous reports have
Figure 6. Analysis of Treg cells expanded by IL-2Jc during ECM. A) Viable Foxp3
+ CD4
+ Treg cells (GFP
pos), and Foxp3
2 CD4
+ non-Treg cells
(GFP
neg) were cell sorted from the spleens of naı ¨ve foxp3
gfp/gfp mice. 1610
6 GFP
pos cells or 5610
6 GFP
neg cells were adoptively transferred into mice,
which were then infected with PbA, and treated either with IL-2Jc or control saline. Four days later, numbers of splenic GFP
+ CD4
+ T cells were
enumerated. B) Naı ¨ve C57BL/6 mice, and those infected with PbA, were treated with IL-2Jc or control saline. Four days later, spleens were isolated,
Foxp3
+ CD4
+ T cells were enumerated by flow cytometry, and IL-10 and IFNc production by these cells was assessed directly ex vivo by intracellular
cytokine staining. C) Four days after infection with PbA, splenic CD4
+ Foxp3
+ T cells from IL-2Jc treated and control saline treated mice we assessed
for expression of CD25, Foxp3 and CTLA-4 by flow cytometry. Mann-Whitney: ***p,0.001; **p,0.01; *p,0.05; NS-not statistically significant.
doi:10.1371/journal.ppat.1001221.g006
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expressing Treg cells, and that enhanced IL-10 levels protect
against ECM [49,50]. Our data is consistent with a moderate
therapeutic role for IL-10 in ECM, but demonstrates that CTLA-
4 is a more potent regulator of pathogenic T cell responses. We
attempted to determine the antigen specificity of the IL-10
response made by Tregs cells in IL-2Jc treated mice, by sorting
these cells, stimulating with APC and parasite antigen, and
looking for IL-10 production at both the protein and mRNA
level. However, these experiments are notoriously difficult to
perform [51,52,53], and we were unable to assess the antigen
specificity of IL-10 producing Tregs. There may also be different
roles for the major regulatory molecules produced by Treg cells
in our study (CTLA-4) and inducible regulatory T cells identified
by others (IL-10; [4,40]), by acting on different cellular/tissue
targets during malaria. However, there is no direct evidence for
this as yet.
In conclusion, we and others have shown that Treg cells
numbers expand during malaria infection, but are unable to
protect against T cell mediated immune pathology [20,21,40].
Here we show for the first time that Treg cells can protect against
T cell-mediated immune pathology in malaria if their numbers are
sufficiently expanded at the appropriate time during the immune
response. Thus, while increased Treg cell frequencies may
contribute to increased parasitemia in malaria patients [4,44,45],
a further possibility is that these cells expand in an attempt to
protect against disease caused by parasite sequestration.
Materials and Methods
Mice
Female C57BL/6 mice and congenic CD45.1
+ C57BL/6 mice
aged 6–8 weeks were purchased from the Australian Resource
Centre (Canning Vale, Perth, Western Australia) and maintained
under conventional conditions. DEREG mice [5], OTI [54],
C57BL/6 il10
2/2, and C57BL/6 Jalpha18
2/2 mice were bred
and maintained in house. foxp3
gfp/gfp mice [41] were backcrossed
ten times onto the C57BL/6 background, bred and maintained in
house.
Ethics statement
All animal procedures were approved and monitored by the
Queensland Institute of Medical Research Animal Ethics Commit-
tee. This work was conducted under QIMR animal ethics approval
number A02-633M, in accordance with the ‘‘Australian code of
practice for the care and use of animals for scientific purposes’’
(Australian National Health & Medical Research Council).
Parasites and infections
P. berghei ANKA (PbA) strains were used in all experiments after
one in vivo passage in mice. A transgenic PbA (231c1l) clonal line
expressing luciferase and green fluorescent protein under the
control of the EF1-a promoter (PbA-luc) was used for all
experiments unless stated otherwise [20]. Transgenic PbA strains
expressing model T cell epitopes, and control strains, PbTG and
Figure 7. IL-2Jc-mediated protection against ECM is dependent on Foxp3
+ cells. C57BL/6 and DEREG mice (n=5–6) were PbA-infected and
treated with IL-2Jc or saline on the same day. IL-2Jc-treated C57BL/6 and DEREG mice were i.p. treated on days 3, 5, & 7 p.i. with 1mg of DT or saline.
A) On day 4 p.i. blood CD4
+ T cells were analysed by flow cytometry for the presence of GFP
+ Foxp3
+ Treg cells. B) Mice (C57BL/6: upper
graph)(DEREG: lower graph) were monitored for clinical symptoms from day 5 p.i. (120 hours p.i.). These data are representative of 2 independent
experiments. C) C57BL/6 mice and DEREG mice (n=5–7) were IL-2Jc or control saline treated on the day of infection with PbA. All mice were DT
treated, and on day 6 p.i. whole body parasite burdens were assessed. Mann-Whitney: **p,0.01.
doi:10.1371/journal.ppat.1001221.g007
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Melbourne, Australia, and were maintained and used as previously
reported [35]. All mice were infected with 10
5 pRBCs intravenously
(i.v.) via the lateral tail vein. Blood parasitemia was monitored by
examination of Diff-Quick (Lab Aids, Narrabeen, NSW, Australia)
stained thin blood smears obtained from tail bleeds.
Disease assessment
Mice were monitored twice daily after day 5 p.i., and clinical
ECM evaluated. Clinical ECM scores were defined by the
presentation of the following signs: ruffled fur, hunching, wobbly
gait, limb paralysis, convulsions, and coma. Each sign was given a
score of 1. Animals withsevere ECM (accumulative scores=4) were
sacrificed by CO2 asphyxiation according to ethics guidelines, and
the following timepoint given a score of 5 to denote death.
Antibodies and other reagents
Allophycocyanin (APC) or Pacific Blue (PB)-conjugated anti-
TCRb chain, phycoerythrin(PE)-Cy5- or PE-conjugated anti-CD4,
PE-Cy5-conjugated anti-CD8, PE or fluorescein isothiocyanate-
conjugated anti-CD45.1, APC or PE-conjugated anti-IFNc,a n d
PE-conjugated anti-IL-10 were purchased from Biolegend (San
Diego,CA) or BD Biosciences (Franklin Lakes, NJ). Alexa-647-
labelled anti-mouse Foxp3 mAb was purchased from eBioscience
(San Diego, CA). PE-conjugated anti-human Granzyme B (GzmB),
with mouse cross reactivity, was purchased from Invitrogen (Mount
Waverley, Vic., Australia). Anti-CTLA-4 (UC10-4F10-11) and
control IgG was purchased from BioXCell, (West Lebanon, NH,
USA). Anti-IL-10R (1B1.3a), anti-CD4 (YTS191), anti-IL-2 (S4B6
and JES6-1A12), anti-NK1.1 (PK136), and isotype control mAb
(MAC49; ratIgG1) were purified from culture supernatants by
protein G column purification (Amersham, Uppsala, Sweden)
followed by endotoxin removal (Mustang Membranes; PallLife
Sciences, East Hills, NY). Purified control rat IgG were also used in
some experiments and purchased from Sigma-Aldrich (Castle Hill,
NSW, Australia). Diphtheria toxin (DT) was purchased from
Sigma-Aldrich, diluted in saline, and 1mg doses injected via the
intraperitoneal route.
Figure 8. IL-2Jc-mediated protection against ECM is dependent on CTLA-4 more than IL-10. C57BL/6 mice (n=10–20 per group) were
PbA-infected, and treated with IL-2Jc or control saline. On days 3 and 5 p.i. mice were i.p. treated with 0.5mg of anti-CTLA-4 mAb, anti-IL-10R mAb, or
control rat IgG antibodies. Mice were monitored for A) survival, B) whole body parasite burden on day 6 p.i., with some groups also being analysed
for C) splenic IFNc
+ CD4
+ T cell responses on day 4 p.i. Data in A) are pooled from 3 independent experiments, with statistical comparisons made
relative to the ‘‘saline + Rat IgG’’ group. Log Rank tests performed in A), and Mann-Whitney tests in B) & C) ***p,0.001; *p,0.05; NS-not statistically
significant.
doi:10.1371/journal.ppat.1001221.g008
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complexes
1.5mg of recombinant murine IL-2 (eBioscience, San Diego,
CA) was incubated with 50mgo fe i t h e rS 4 B 6o rJ E S 6 - 1 A 1 2
(prepared as detailed above) in saline, for 30 minutes at 37uC
prior to intraperitoneal administration to each mouse in a volume
of 200ml.
Preparation of tissue mononuclear cells
Blood mononuclear cells were analysed in heparinised blood
after 2 rounds of red cell lysis using hypotonic red cell lysis buffer
according to the manufacturer’s instructions (Sigma-Aldrich).
Spleen cells were isolated by passing tissue through a 100-mm
sieve in RPMI-1640 tissue culture medium supplemented with 2%
(v/v) fetal calf serum (Wash Buffer). Red blood cells were lysed as
Figure 9. A proposed model for the roles of Treg cells in ECM. A). Following PbA infection of C57BL/6 mice, Treg cells suppress potent anti-
parasitic T cells responses, but the PbA-specific T cell responses that do emerge promote parasite tissue sequestration, resulting in disease and death.
However, if Treg cells can be expanded and activated sufficiently by early signalling via the high affinity IL-2 receptor, they can prevent pathogenicT
cell responses mediating parasite tissue sequestration. B). The removal of CD25
hi Treg cells prior to PbA infection allows the generation of a potent
anti-parasitic CD4
+ T cell response, but also the re-emergence of CD25
hi Treg cells during the course of infection, resulting in an enhanced and
qualitatively better anti-parasitic CD4
+ T cells response that controls parasite growth and a mechanism to prevent parasite tissue sequestration. In
contrast, if all Treg cells are depleted prior to infection, as is the case when DEREG mice are treated with DT, a balance between emerging anti-
parasitic CD4
+ T cell responses and expanding Treg cell responses is not achieved, and T cell-mediated immune pathology occurs. Conventional CD4
+
(blue) and CD8
+ (green) T cells, as well as CD25
hi (red) and CD25
lo or negative (purple) Treg cells are shown and disease outcome in different
experimental conditions is shown.
doi:10.1371/journal.ppat.1001221.g009
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Brain mononuclear cells were isolated by digesting tissue in
collagenase type 4 (1 mg/ml; Worthington Biochemical Corp.,
Lakewood, NJ) and deoxyribonuclease I (0.5 mg/ml; Worthington
Biochemical) at room temperature for 40 minutes, before passing
through a 100-mm sieve and washing twice with Wash Buffer. The
cell pellet was resuspended in 33% (v/v) Percoll in PBS and
centrifuged at 6936g for 12 minutes at room temperature.
Supernatant containing debris was removed, and the leukocyte
pellet was washed once in Wash Buffer, red blood cells lysed as
described above, and washed and resuspended in RPMI-1640
medium supplemented with 5% (v/v) fetal calf serum.
Flow cytometric analysis
For the staining of cell surface antigens, cells were incubated
with fluorochrome-conjugated mAbs on ice for 20 minutes.
Intracellular staining for Foxp3 was performed on fixed/
permeabilized cells using Alexa647-labeled anti-mouse Foxp3 kit
(eBioscience), according to the manufacturer’s instructions.
Intracellular cytokine staining for IFNc, CTLA-4 and GzmB
was performed using a BD Fixation/Permeabilisation kit (BD
Biosciences) according to manufacturer’s instructions. Data were
acquired on a FACSCanto II flow cytometer (BD Biosciences) and
analysed using FlowJo software (Treestar, Ashland, OR, USA).
Cell populations in the blood, spleen and brain were defined as
follows: CD4
+ T cells (CD4
+TCRb
+), CD8
+T cells
(CD8a
+TCRb
+), NK cells (NK1.1
+TCRb
2), CD4
+ Treg cells
(CD4
+Foxp3
+TCRb
+). Cytokines in tissue culture supernatants
and serum samples were quantified using the cytometric bead
array flexsets (BD Biosciences) on a FACSarray equipped with BD
Flexset analysis software (BD Biosciences).
Ex vivo antigen restimulation of CD4+ T cells
Splenic CD4
+ T cells (5610
4 cells/well), either bulk populations
purified to .85% purity by magnetic bead positive selection
techniques (Miltenyi Biotec; North Ryde, NSW, Australia), or cell
sorted to isolate Treg cells from foxp3
gfp/gfp mice to a purity .99%,
were stimulated with 2.5610
5 PbA-parasitized RBC (pRBC) or
naive RBC (nRBC), and 1610
6 irradiated naive C57BL/6 spleen
cells at 37uC in 5% (v/v) CO2. Cell culture supernatant was
collected after 24h or 72 h and cytokines were measured as above
(BD Biosciences). After 72 h of culture, cells were pulsed with
1 mCi [
3H]thymidine for 18 h, before measuring thymidine
incorporation using a Betaplate Reader (Wallac).
In vivo bioluminescence imaging
Luciferase-expressing PbA pRBCs were visualized by imaging
whole bodies or dissected organs with an I-CCD photon-counting
video camera and in vivo imaging system (IVIS 100; Xenogen,
Alameda, CA). Mice were anesthetized with isofluorane and
injected intraperitoneally with 0.1 ml of 5 mg/ml D-luciferin
firefly potassium salt (Xenogen). 5 minutes afterwards, images
were captured on the IVIS 100 according to the manufacturer’s
instructions. Parasites were visualized in the brain after removal
from mice that had been perfused with 15ml of saline via the
heart. Bioluminescence generated by luciferase transgenic PbAi n
mice or brain tissue was measured according to the manufacturer’s
instructions. The unit of measurement was photons/second/cm
2/
steer radiant (p/sec/cm
2/sr).
Statistical analysis
Differences in survival of treatment groups were analysed using
the Kaplan-Meier log-rank test. All other analyses of differences in
parasitemia, cytokine levels, cell numbers, bioluminescence etc.
were performed using the Mann-Whitney nonparametric test. For
all statistical tests, p,0.05 was considered significant. In all figures,
*, **, *** denote p values of p,0.05, p,0.01 & p,0.001
respectively.
Supporting Information
Figure S1 IL-2Jc-mediated protection against ECM is
independent of NK cells and invariant NKT cells. A)
C57BL/6 mice (n=5) were infected and treated with IL-2Jc, IL-
2Sc or control saline for 24 hours. Splenic NK cells (NK1.1
+
TCR
2) and NKT cells (NK1.1
+ TCR
+) were assessed directly ex
vivo for expression of CD69, GzmB and IFNc by flow cytometry.
Mann-Whitney tests performed relative to saline-treated, infected
mice: **p,0.01; NS=not statistically significant. B & C) C57BL/
6 wild-type mice (n=5), treated with anti-NK1.1 or control IgG
(0.5mg i.p on days 22, +1 and +4 p.i.), and Ja18
2/2 mice (n=5)
were infected and treated with IL-2Jc or control saline. B) The
percentage of CD4
+ T cells in the blood expressing Foxp3 was
determined on Day 4 p.i. C) Parasite burdens were determined on
Day 6 p.i. Mann-Whitney tests performed relative to each saline-
treated control group: **p,0.01 *p,0.05.
Found at: doi:10.1371/journal.ppat.1001221.s001 (0.09 MB TIF)
Figure S2 IL-2Jc blocks serum IFNc production during
ECM. Serum from naı ¨ve C57BL/6 mice (n=5), and PbA-infected
and variously treated mice was assessed for IFNc on day 4 p.i.;
Mann-Whitney: **p,0.01. This data is representative of 3
independent experiments.
Found at: doi:10.1371/journal.ppat.1001221.s002 (0.14 MB TIF)
Figure S3 Ex vivo CD4
+ T cell antigen-specific recall
responses are reduced in IL-2Jc treated mice: On day 4
p.i., CD4
+ splenocytes were isolated from individual naı ¨ve, PbA-
infected & saline treated, and PbA-infected & IL-2Jc or IL-2Sc
treated C57BL/6 mice (n=5). A) Cells from individual mice were
stimulated with parasitized RBC (pRBC), or non-parasitized RBC
(nRBC) and the ratio of antigen-specific proliferation in response
to pRBC relative to nRBC was determined per mouse. B)
Supernatants from stimulated CD4
+ spleen cells were assessed for
IFNc levels. Mann-Whitney: ** p,0.01; *** p,0.001.
Found at: doi:10.1371/journal.ppat.1001221.s003 (0.48 MB TIF)
Figure S4 IL-10 is not essential for IL-2Jc mediated
protection against ECM. IL-10
2/2 C57BL/6 mice (n=10–
20) were infected with PbA, and immediately treated with IL-2Jc
or control saline. On days 3 & 5 p.i., IL-2Jc treated IL-10
2/2 mice
were injected i.p. with 0.5mg of anti-CTLA-4 or control IgG.
Mice were monitored for survival. Statistical analyses indicate
comparison with saline treated mice: Log Rank: ** p,0.01; ***
p,0.001. Data is pooled from 2 independent experiments.
Found at: doi:10.1371/journal.ppat.1001221.s004 (0.10 MB TIF)
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